I'm LongbridgeAI, I can summarize articles.Amicus Therapeutics has fully repaid and terminated its loan agreement with Blackstone, originally dated October 2, 2023, in connection with its merger closing on April 27, 2026. The termination, which incurs no exit fees, simplifies the company's capital structure post-transaction. The agreement involved Blackstone Alternative Credit Advisors, Blackstone Life Sciences Advisors, and Wilmington Trust as the agent.
Amicus Therapeutics repaid in full all outstanding amounts and terminated all commitments under its Oct. 2, 2023 loan agreement in connection with the merger closing on Apr. 27, 2026. The facility, arranged with Blackstone Alternative Credit Advisors, Blackstone Life Sciences Advisors and certain lenders with Wilmington Trust as agent, was fully discharged and the related guarantees and liens were released. The early termination carries no disclosed exit fees and is expected to simplify the company's capital structure post-transaction.
Agreement details:
- Agreement terminated: Secured loan agreement (Amicus Credit Agreement)
- Counterparty: Blackstone Alternative Credit Advisors; Blackstone Life Sciences Advisors; Wilmington Trust (agent); certain lenders
- Original agreement date: Oct 02 2023
- Termination date: Apr 27 2026
- Termination type: Early
- Exit fees / payments: None
- Reason: Repayment in full upon merger closing
Original SEC Filing: AMICUS THERAPEUTICS, INC. [ FOLD ] - 8-K - Apr. 27, 2026